CAPLYTA demonstrated a statistically significant extension in time to relapse. How meaningful is this finding for schizophrenia patients in terms of disease management, and what impact could it have on long-term outcomes?

The study results indicated a generally favorable safety profile for CAPLYTA, with headache as the most common adverse event. Given the safety challenges associated with antipsychotics, how does CAPLYTA's tolerability profile position it as a potential long-term maintenance option?

With a 63% reduction in the risk of relapse compared to placebo, how does CAPLYTA's efficacy compare to other maintenance therapies for schizophrenia, and what might this mean for clinical decision-making in relapse prevention?

For patients managing chronic schizophrenia, adherence to treatment is often a barrier. In your view, could CAPLYTA’s safety and efficacy profile help improve patient adherence, and what other factors play a role in achieving better outcomes in relapse prevention?

CAPLYTA’s mechanism includes serotonin and dopamine receptor activity. How might this unique action impact the treatment of schizophrenia symptoms, and could it provide an advantage over more conventional antipsychotics?

CAPLYTA also extended time to all-cause discontinuation in this study. How important is this endpoint for understanding CAPLYTA’s potential role in long-term schizophrenia care?

Intra-Cellular Therapies has been exploring CAPLYTA for multiple mental health conditions. What do you see as the potential for CAPLYTA in addressing other psychiatric disorders, and what might be the impact of such an approach?

What are the remaining unmet needs in schizophrenia maintenance treatment, and how do you envision CAPLYTA fitting into the evolving landscape of mental health therapeutics?